Leaflet LAMIVUDINA/ZIDOVUDINA SANDOZ 150mg / 300mg film-coated tablets

Product code:
W64236002
Quantity:
120
Indicated for:
HIV-1 infection
Route of administration:
oral
Substance:
lamivudine + zidovudine (nucleoside/nucleotide reverse transcriptase inhibitors)
ATC
J05AR01 — Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Precautions:

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.

The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.

The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.

This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.

General data about LAMIVUDINA/ZIDOVUDINA SANDOZ 150mg / 300mg

Substance:
lamivudine + zidovudine
Date of latest medicines list:
01-05-2018
Product code:
W64236002
Concentration:
150mg / 300mg
Pharmaceutical form:
film-coated tablets
Quantity:
120
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PHARMADOX HEALTHCARE LTD. - MALTA
Holder:
SANDOZ S.R.L. - ROMANIA
Number:
10471/2017/02
Shelf life:
3 years

Combinations with other substances